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REVIEW ARTICLE 
THE RELEVANCE OF META-ANALYSIS, SYSTEMATIC REVIEWS 




Traditional review articles provide clinicians with syntheses of the medical literature but are 
criticised as being haphazard in their methodology and biased in their conclusions. Systematic 
reviews use rigorous methods to minimise bias and statistical methods to synthesise results 
(meta-analysis) that increase power and precision. They permit investigation of generalisability 
and consistency, improve transparency of methodology, and enhance reproducibility. This article 
examines the science of systematic reviews and meta-analysis and their relevance to clinical 
psychiatry. It evaluates the potential errors and sources of bias of meta-analysis, and offers 
guidelines for evaluation of systematic reviews. It highlights the efforts of the Cochrane 
Collaboration which is an international organisation involved in preparing, maintaining and 
disseminating highly structured, frequently updated, and good quality systematic reviews of the 
effects of interventions in all aspects of health care. 
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The relevance of meta-analysis to 
psychiatry stems from one of the earliest 
meta-analysis ever undertaken, that evaluated 
the efficacy of various forms of psychotherapy 
(Smith & Glass, 1977). Since the 1980's, 
meta-analysis have increasingly appeared in the 
medical literature, and scarcely a month now 
passes without the publication of a meta-analy-
sis of relevance to clinical psychiatry in 
general medical journals or in mainstream 
psychiatric literature. 
The term meta-analysis', or the 'analy-
sis of analyses', was coined by Glass (1976). 
I The term meta-analysis is slowly being replaced 
| by the term 'overviews' or, more recently, 
j 'systematic reviews'. The Potsdam International 
Consultation on Meta-analysis in 1994 provided 
the following definitions of terminology: 
Systematic Review (or Overview): the 
application of scientific strategies that limit bias 
to the systematic assembly, critical appraisal, 
and synthesis of all relevant studies on a 
specific topic. Meta-analysis (or Quantitative 
Overview): a systematic review that employs 
statistical methods to combine and summarise 
the results of several studies (Cook et al., 1995). 
Why do we need systematic reviews ? 
Health care providers, researchers and 
policy makers are inundated with unmanage-
able amounts of information and need some 
method of summarising this for efficient deci-
sion making. The traditional review article has 
provided one way of synthesising the relevant 
articles into digestible amounts of information. 
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Often written by experts who are opinion 
leaders in their fields, these traditional or 
subjective reviews have been influential in 
directing research and clinical decision making. 
1) Superiority over traditional reviews; 
Traditional reviews have, however, been 
criticised as being haphazard and biased, 
subject to the idiosyncratic impressions of the 
individual reviewer (Mulrow, 1987), and rarely 
as scientific in methodology as the studies they 
review (Haynes, 1992). An attempt to answer a 
clinical question on the efficacy of Electrocon-
vulsive Therapy (ECT) in schizophrenia by 
consulting traditional reviews in journals, 
specialist and general psychiatric text -books, 
disconcertingly revealed that there was little 
agreement on studies selected for review, as 
well as in crucial aspects of management 
(Tharyan, 1997). 
On the other hand, systematic reviews 
and meta-analysis apply explicit scientific 
principles aimed at reducing random and 
systematic errors (Oxman et al., 1988). This 
permits replication and enables one to 
understand why results and conclusions of some 
reviews differ. 
Traditional reviews lag behind and often 
vary significantly from continuously updated or 
cumulative meta-analysis. Cumulative 
meta-analysis refers to the performance of a 
meta-analysis every time a new trial appears, 
providing practitioners with up-to-date 
information on emerging and established 
advances." Lau et al. (1992) demonstrated the 
advantage of cumulative meta-analysis when 
they evaluated 33 trials done on the use of 
intravenous streptokinase as thrombolytic 
therapy for myocardial infarction conducted 
between 1959 and 1988. They found that a 
consistent, statistically significant reduction in 
total mortality (odds ratio, 0.74: 95% CI 
0.59-0.92) was achieved in 1973, after only 8 
trials involving 2432 patients had been 
completed. The results of the 25 subsequent 
trials involving 34,542 patients till 1989 
(including two very large, expensive trials 
involving 11,712 patients and 17,187 patients) 
had little or no effect on the odds ratio 
establishing efficacy, but simply narrowed down 
the confidence interval. This suggests that 
intravenous streptokinase could have been 
shown to be life saving almost 20 years before 
it's general adoption to clinical practice. 
Similarly, Antman et al. (1992) using 
cumulative meta-analysis showed that pooled 
data from 15 randomised trials published 
before 1990 found no evidence of mortality 
reduction associated with prophylactic lidocaine 
for acute myocardial infarction. Despite this 
evidence, most traditional reviews and expert 
recommendations in text-books on the topic at 
that time continued to recommend 
prophylactic lidocaine and many effective 
treatments were not being recommended. 
Cumulative meta-analysis has the potential to 
provide information to reduce the need for 
future large trials (Lau et al., 1995) 
2. Increased power: 
Even a well-conducted randomised 
control trial may have insufficient power to 
demonstrate an effect convincingly, unless the 
effect of the intervention is very strong or the 
trial is very large. In general, the real difference 
between two treatments, in many important 
outcomes, are often not large, but may be 
clinically important. Many studies with negative 
results do not have sample sizes large enough 
to even detect a 50% difference between 
treatments (Sackett, 1979). By combining 
results of several trials, meta-analysis provide 
a 'tower of power' that increases the sample 
size and thus the power to detect significant 
differences (Mulrow, 1994). This is readily 
apparent in the Cochrane Collaboration's logo 
(Fig. 1). This graphically depicts, as Odds 
Ratios (OR) and Confidence Intervals (CI), the 
results of 7 trials that evaluated the effects of a 
short course of corticosteroids given to women 
expected to give birth prematurely, with the 
outcome depicted being neonatal death. In 
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graphical displays of meta-analysis, sometimes 
/called 'forest plots', if the odds ratios for 
(negative outcomes lie to the left of the midline 
<OR < 1) the results favour the experimental 
treatment, while the reverse (OR > 1) favour 
the control condition. The midline represents the 
point of no significant difference (OR = 1). In 
Figure 1, only two trials had clear-cut 
statistically significant results, graphically 
depicted as the two trials whose confidence 
intervals lie entirely to the left of the midline. 
The other five trial results were not statistically 
significant as is evident from the confidence 
intervals straddling the midline. Using the 
traditional 'vote counting approach', the 
conclusion drawn would be that there is no 
evidence to indicate that corticosteroids reduce 
neonatal mortality, since the number of 
inconclusive studies outnumber the positive 
studies. However, when data from all of the 
studies were pooled, this yielded a definitive 
significant combined effects estimate 
(represented by the diamond to the left of the 
midline demonstrating a positive treatment 
effect), which indicated strongly that 
corticosteroids reduce neonatal mortality from 
complications of immaturity. 
significant benefit, with 14 of them showing an 
unfavourable result. Combination of the results 
of the 24 trials based on about 20,000 subjects 
yielded a pooled odds ratio of 0.77 (95% 
CI = 0.70-0.85; note the narrow confidence 
intervals); i.e. mortality was 23% (CI between 
15 -30 %) lower in treated patients than in 
controls. This demonstrates the greater 
precision with meta-analysis compared to the 
'vote co nting' approach. 
This is largely due to, the differential 
weighting of studies and evaluation of weighted 
pooled data in meta-analysis, while with the 
'vote counting' approach, equal weights are 
assigned to all studies irrespective of quality, 
sample size, magnitude of effect, or precision 
of results, with inappropriate over-reliance on 
significant 'p values'. 
It is important to remember that results 
that achieve conventional levels of significance 
(p < 0.05) merely tell us that the results are 
less likely to be accounted for by chance. The 
use of odds ratios and confidence intervals (a 
measure of statistical uncertainty), enables 
estimation of the size of the effect of 
intervention as well as the range within which 
the true effect may plausibly lie (Gardner & 
Altman, 1986). 
FIGURE 1: THE COCHRANE COLLABORATION LOGO 
J The diamond at the bottom represents pooled odds ratios Pooling data provides power' and 
2 reveals significant effect* that individual smell studies are unable to do 
I 
|3. Increased precision: 
Yusuf et al. (1985) assessed 24 RCTs that 
'evaluated mortality reduction by the long-term 
use of beta-blockers after myocardial infarction. 
Four trials showed results that were in favour of 
.beta-blockers, while twenty trials found no 
4. Generalisability and consistency: 
Since different studies use different 
populations, designs, definitions, measure-
ments and variations in treatment, systematic 
reviews provide an opportunity to assess the 
generalisability of findings that is not possible 
with individual studies. 
Consistency of results of whether effects are in 
the same direction, and of similar magnitudes, 
can be made and reasons for inconsistency can 
be explored. 
PITFALLS OF META-ANALYSIS 
Meta-analysis have been likened to 'an 
exercise in mega silliness', with the major con-
tention that including all material - good, bad, 
and indifferent- in a meta-analysis delegates to 
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the reader the subjective judgements that 
meta-analysis was designed to avoid Over the 
past decade critiques of meta-analysis have 
increasingly appeared in medical literature 
(Goodman, 1991; Shapiro, 1994, Egger & 
Smith, 1995; Feinstein, 1995; Bailar, 1995 & 
1997; Naylor, 1997) These articles raise a 
number of questions. 
1) Can meta-analysis be trusted? 
There are many problems in conducting 
meta-analysis and erroneous results are 
sometimes produced. A meta-analysis of 7 
RCTs provided evidence for the effectiveness 
of intravenous magnesium, in the treatment of 
patients with suspected myocardial infarction 
(Teoet al., 1991). 
However, the results of a mega trial, the 
ISIS 4 trial, have called into question the 
results of the meta-analysis and the effective-
ness of magnesium (The ISIS-4 Collaborative 
Group, 1995). 
The predictive ability of meta-analysis of 
RCTs have been questioned by Villar et al. 
(1995). More recently, important discrepancies, 
mainly in relation to the size of the effect rather 
than the direction, were detected between 
published meta-analysis and subsequent large 
randomised controlled trials on the same topic 
(LeLorieret al., 1997). Adherence to guidelines 
for systematic reviews for RCTs (Cook et al., 
1995) could reduce such errors, though 
possibly not completely eliminate them. It 
therefore behoves readers of systematic reviews 
to be aware of potential sources of errors and 
bias 
2) What are the sources of bias in systematic 
reviews and meta-analysis? 
Systematic reviews and meta-analysis 
are retrospective observational studies 
intermediate in design between primary 
research and traditional narrative' reviews. The 
units of observation are the results obtained 
from other studies, hence the reviewer has many 
constraints that can lead to biases and 
subsequent errors. The following are common 
sources of bias (Felson, 1992: Mulrow & ,( 
Oxman, 1994; Bailar. 1997; Naylor, 1997). . 
t 
A) Sampling bias; 
One of the challenges, and an important 
aspect of the validity, of a systematic review is 
the complete identification of all relevant stud-
ies. Biases in sampling could occur due to any 
of the following: 
i) Publication bias. This refers to the tendency 
for studies that report statistically significant 
results to be published. Unpublished studies are 
likely to have negative results as well as smaller 
sample sizes. Reliance only on the results of 
published trials produces over-estimates of 
treatment effects and leads to erroneous 
conclusions ttiat could prove detrimental to 
patient care (Egger & Smith, 1995). 
Publication bias often arises due to au-
thors of negative trials not submitting manu-
 f 
scripts for publication (Rosenthal. 1979), edito-
rial and referees' policy in not publishing stud-
ies with results that challenge conventional be-
liefs (Dickersin. 1990), and conflicts of interest 
caused by drug companies discouraging publi-
cation of sponsored trials with negative or ad-
verse results (Dickersin. 1990). Non-English-
language references are under-represented in 
electronic databases such as MEDLINE and 
only published articles are included, so depend-
ing only on MEDLINE increases the potential 
for publication bias (Dickersin etal. 1987). and 
language bias (Easterbrook et al., 1991). To 
protect against bias and ensure that all relevant 
data are included in a review it is important to 
use multiple sources to identify relevant trials 
(Dickersin et al., 1994). 
The importance of publication bias has 
been recently recognised by editors of over a ' 
100 journals around the world who have called 
for authors of unpublished controlled trials (in-
cluding those trials published only as abstracts) 
to submit them for registration. The aim is to 
increase accessibility of these trials to those 
wishing to do systematic reviews (Smith & 
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^Roberts. 1997). 
L There are some ways to assess the 
^presence and magnitude of publication bias in 
1 systematic reviews, though none of them are 
fully validated. One method is the computation 
of the "fail-safe number" which is the number of 
unpublished studies that would be needed to 
change the results of a meta-analysis 
(Rosenthal. 1979). If the fail-safe number' is 
very large, then publication bias is unlikely to 
;have an effect on the results o? the meta-analy-
sis. The other is thr; use of the "funnel plot" 
(Mulrow & C<man, 1994). This is a simple 
graphical test where Uie effect size or the odds 
ratios of the studies is plotted against the sam-
ple size or the study weight (usually the inverse 
of the variance of the odds ratio). If there is no 
publication bias the plot would resemble an in-
verted funnel with larger studies (with greater 
weights) at the top in the middle and smaller 
studies spread at the bottom. If one assumes 
.that odds ratios greater than one favours the 
I control condition, a gap in the bottom right of 
5 the funnel (Figure 2) indicates that negative 
I studies with small sample sizes were not identi-
\ fied (the most common scenario). A gap on the 
i bottom left side indicates that smaller positive 
studies were missed. 
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The ultimate way to avoid publication bias 
is to build a comprehensive register of published 
and unpublished trials preferably for each spe-
1 ciality (Adams & Gelder, 1994), and to prospec-
I tively register trials at the stage after research 
I & ethics committee approval is obtained (Naylor, 
1997). 
li) Retrieval bias. Electronic databases such as 
MEDLINE (the electronic form of Index 
Medicus) and EMBASE (the electronic form of 
excerpta medica) are powerful tools for 
locating studies. 
However, only 30 - 80% of all known 
published randomised controlled trials are 
identifiable using MEDLINE, depending on the 
area or specific question (Dickersinetal., 1994). 
In the field of mental health, MEDLINE searches 
failed to identify 30-50% of RCTs while hand-
searching journals identified 95% of the trials 
(Adams et al., 1994). Many journals are not 
indexed in MEDLINE and many articles in 
indexed journals do not provide sufficient 
information to permit proper indexing. 
Moreover, the retrieval rate increases with the 
expertise of the retriever and the casual 
searcher is unlikely to retrieve a majority of 
indexed trials (Dickersin et al., 1994). 
It is often necessary to search more than 
one electronic database, as the overlap in 
journals covered by MEDLINE and EMBASE is 
only approximately 34% (ranging from 10% to 
75%) (Mulrow & Oxman, 1994). Other strate-
gies to improve comprehensiveness of the 
search for trials are checking cross-references 
of retrieved trials and consulting references in 
existing 'narrative' reviews though one needs 
to guard against 'reference bias' (Gotzsche, 
1987) which is the tendency to selectively quote 
references that agree with the authors' view-
point. Personal communication with authors of 
trials, experts in the field, pharmaceutical com-
panies or manufacturers of equipment (e.g. ECT 
machines), hand-searching journals and con-
ference abstracts, though also subject to 'refer-
ence bias', are potentially useful to complete 
retrieval of relevant studies in the 'grey litera-
ture'. 
iii) Multiple publication bias. Not infrequently 
reviewers are faced with the problem of trials 
being published in different journals as a series 
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being recorded as separate trials, thereby 
inflating erroneously the number of participants 
in the meta-analysis. This is more likely if the 
articles are published with different authors, as 
was detected by Huston & Moher (1996), who 
recorded seven different publications with 
different authorship of a single trial of 
Risperidone in chronic schizophrenia. 
B. Selection Bias 
Once trials are identified they are 
usually selected according to inclusion criteria 
predetermined by the reviewers. There are 
various causes of selection bias: i) Inclusion 
criteria bias: The use of inclusion criteria can 
introduce bias if the reviewer consciously or 
otherwise sets criteria in a manner that excludes 
trials he/she is aware of. One of the ways of 
minimising selection bias is to select a 
comprehensive and clearly formulated protocol 
a priori and the manner in which the 
methodological quality of the studies shall be 
critically appraised for relevance and validity. 
Selection bias can be further reduced by two 
(or more) reviewers independently assessing 
trials for inclusion, and further by blinding the 
reviewers to the authors, institutional affiliation, 
as well as to the results of the trials during 
assessment for inclusion. A combination of a 
content expert (with pre-formed opinions that 
can bias assessments of both the relevance and 
validity of articles) and a non-expert (with no 
pre-formed and potentially biased views) may 
confer an advantage in minimising selection 
bias. 
ii) Bias in assessing quality of trials : It is 
important in a systematic review to exclude poor 
quality trials as their inclusion tends to 
exaggerate the overall estimate of treatment 
effects and may lead to incorrect inferences 
(Khan et al., 1996). Hence some criterion of 
quality needs to be applied that is both simple 
to use as well as valid. 
In assessing the quality of trials, four 
sources of bias are relevant: Selection bias, 
performance bias, attrition bias and detection 
bias. The first two are most likely to result in 
biased outcomes (Chalmers, 1983; Schultz, 
1995). Selection bias can be minimised by 
randomisation, though not all so called RCTs 
are really randomised. Empirical research has 
shown that lack of adequate allocation 
concealment during randomisation is associated 
with bias (Chalmers, 1983). Thus trials can be 
judged on the reported method of allocation 
concealment. Performance bias refers to 
systematic differences in care provided to 
comparison groups other than the intervention 
of interest. Double blinding is important in 
protecting against performance bias. There is 
evidence that participants who are aware of their 
assignment status report more symptoms, 
leading to biased results (Sackett, 1979). For 
these reasons, use of" blinding" is often used 
as a criterion for validity, though not all 
supposedly double-blind studies are really 
double- blind (Oxtoby et al., 1989). 
Many scales and checklists have been 
used to assess the validity and "quality" of 
randomised controlled trials (Moher et al., 
1995). Many of the instruments use complicated 
scoring systems, with or without weights, that 
are time consuming, do not improve validity, 
are liable to confuse the quality of reporting with 
the validity of the design and conduct of a trial 
and are not supported by empirical evidence 
(Mulrow & Oxman, 1994). For example, there 
is no empirical basis for determining how much 
weight to assign td different validity criteria. 
Simple approaches to eliminating highly biased 
trials are preferred, though this is an area that 
warrants further evaluation. 
A limitation of assessing quality of trials 
is the poor quality of reporting in many pub-
lished reports, at least from the point of view of 
performing systematic reviews. The application 
of standards for reporting trials (The standards 
for reporting trials group 1994; Altman, 1996) 
can facilitate critical appraisal. 
C. Data extraction bias. 
The accuracy and inter-observer 
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variability of data extraction from trials'as a 
i potential source of bias has been apparent since 
the earliest meta-analysis (Smith & Glass, 
1977). Inter-observer reliability can be 
maximised and extraction bias minimised by the 
use of specific and comprehensive pre-tested 
data-extraction sheets with clear instructions on 
how to interpret and handle data and by 
reviewers working independently duplicating the 
extraction process. Contributing to extraction 
bias may be 'reporting bias' where inadequate 
reporting of data for various outcomes, 
especially unfavourable outcomes, leads to 
biased results. Published data may often need 
to be complemented by additional information 
obtained by personal communication from the 
authors. There is evidence that both 'data ex-
traction bias' and 'reporting bias' can be 
minimised by the use of individual patient data 
in performing meta-analysis (Stewart & Parmar, 
1993), though the effort involved in obtaining 
this may be considerable. This approach may 
be more feasible if trials are prospectively 
registered. 
D. Bias in analysis of results 
The central aim of most systematic 
reviews is to combine the results (meta-analy-
sis) of included trials using a summary statistic 
in order to provide a reliable estimate of the 
effects of an intervention. Typically studies are 
given weights which are usually the inverse of 
the variance; i.e. more precise estimates (from 
If. rger studies with more events) are given more 
weight. Each study is summarised using a 
measure of effect (such as an odds ratio or a 
relative risk for dichotomous data, using the 
Mantel -Haenszel technique or the Peto-
modification (Berlin et al., 1989; Yusuf et al., 
11985), or a weighted mean difference for con-
tinuous data). This represents the within study 
comparison of the intervention and control 
groups. The pooled, weighted measures are 
combined to produce the summary statistic, 
usually with confidence intervals that are 
similar to confidence intervals in single studies. 
This ensures that participants in each study are 
only compared to people in the same study, thus 
preserving the power of randomisation. 
Reviews that use absolute measures 
(Absolute Risk Reduction, Number Needed to 
Treat, Number Needed to Harm) in addition to 
relative measures (Relative Risk Reduction) 
provide useful information for clinicians and 
health planners. The Number Needed to Treat 
(NNT) is an estimate, from the meta-analysis, 
of the number of persons who must be treated 
with an intervention to result in a positive out-
come or to prevent an adverse outcome 
(Laupacis et al., 1988). It takes into account 
the baseline risks as well as the magnitude of 
risk reduction and can be easily calculated from 
the pooled estimates (Table 1). 
TABLE 1 
EFFECT MEASURES FOR DICHOTOMOUS DATA 









• Relative risk (RR) = [A/(A+B)]/IC/(C+D)] 




• Absolute risk reduction (ARR) = A/ (A+B)-C/(C+D) 
• Number needed to treat NNT = 1/ARR 
No other aspect of systematic reviewing 
has generated more criticism than this attempt 
to statistically combine and present a single es-
timate (Bailar, 1997). 
i) Inappropriate statistical methods ; In early 
studies, and even on occasion at present, a 
meta-analysis is published where an "effect 
size" is calculated for each study group based 
on the difference in outcomes before and after 
treatment, and groups from different studies are 
directly compared with each other. When this 
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is done, the power of randomisation is com-
pletely lost and the results are often invalid 
(Mulrow & Oxman, 1994). 
ii) Inappropriate use of statistics : Not all 
systematic reviews should statistically combine 
results The chief reasons tor not doing so are 
inadequate data, or if it does not make sense to 
combine disparate results or outcome 
measures, or if there is significant heterogene-
ity between studies that cannot be explained 
on methodological grounds. Inappropriate 
pooling of data can do more harm than good 
(Naylor, 1997). 
iii) Dealing with heterogeneity : There are two 
types of heterogeneity in relation to systematic 
reviews. Clinical heterogeneity refers to the 
differences in studies due to differences in 
participant characteristics, interventions, and 
trial methodology. Statistical heterogeneity 
refers to incompatibility in the statistical results. 
The former may lead to the latter. There are 
two ways of evaluating for statistical heteroge-
neity. One way of doing this is to look at a graphi-
cal display of the results. If the confidence in-
tervals for the results of each study do not over-
lap, it suggests that the differences are likely to 
be "statistically significant". Figure 3 provides 
an example of statistical heterogeneity from a 
comparison of ECT versus sham ECT in 
schizophrenia with the outcome under 
evaluation being numbers not improved at the 
end of the course of ECT (Tharyan, 1998). The 
pooled data suggests that ECT is superior to 
Sham ECT in the short term (odds ratio 0.48, 
confidence intervals 0.30-0.78) with 1 in 5 to 6 
patients likely to benefit (NNT = 5.85). In this 
comparison, however, the confidence intervals 
of two strongly positive studies (Taylor & 
Fleminger, 1980; Brandon et al., 1985) barely 
overlapped with the results of the other studies, 
indicating that these two 'outliers' differed from 
the others significantly. 
The other method of evaluating statisti-
cal heterogeneity is to do a Chi-square test for 
homogeneity. As a rule of thumb, the Chi-square 
statistic has a value equal to it's degrees of 
freedom (one less than the number of trials); 
values larger than the degrees of freedom (df) 
would give smaller P values and indicate sig-
nificant statistical heterogeneity (Thompson, 
1995). In Figure 2, the Chi-square value of 14.47 
is greater than the degrees of freedom of 5 with 
a Z score of 2.99 yielding a p value of < 0.005 
(from a standard table of cumulative normal 
distribution) and confirming statistically signifi-
cant heterogeneity. When there is "statistically 
significant" heterogeneity, it suggests that the 
observed differences in results are likely to be 
caused by factors other than chance. 
In the presence of heterogeneity, it is 
important to attempt a cautious interpretation 
of likely causes on methodological grounds, 
such as differences in dose, timing or duration 
of treatment, participant characteristics, control 
of bias, and study design. Caution is encour-
aged in explaining heterogeneity since this is 
done post hoc. A careful evaluation of study 
methodology of trials in the meta-analysis in 
Fig 3 reveals that the two strongly positive tri-
als differed from the others in including a pre-
trial stabilisation period with antipsychotics and 
excluding those who improved with antipsychot-
ics. The other trials either did not use antipsy-
chotics in either limb of the trial or did not have 
a significant pre-trial stabilisation period. This 
potentially biased the patients in the two trials 
against further antipsychotic improvement dur-
ing the trial. Re-analyses of the data excluding 
these two trials reduces the strength of the ev»-
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dence, though not the direction of effect. 
Statistical methods (fixed effects versus 
random effects) to evaluate pooled results and 
confidence intervals in the face of significant 
heterogeneity (Berlin et al., 1989; Muirow & 
Oxman, 1994) are beyond the scope of this 
paper. 
iv) Sub-group analyses: In any systematic 
review it is tempting to attempt subgroup 
analysis of, for example, women, older people, 
or those with subtypes of schizophrenia. Sub-
group analyses are common but can be mis-
leading. They should not be done unless, a) 
there is indirect evidence suggesting that the 
difference, if it exists, is plausible, b) the sub-
group analysis is one of a small number tested, 
and stated a priori, in order to prevent spurious 
positive results by chance, c) the difference is 
suggested by comparisons within studies rather 
than between studies, d) the difference is 
consistent across studies, and e) the magnitude 
of the difference is practically important as well 
as statistically significant (Oxman & Guyatt. 
1992). 
It is important to remember that infer-
ences based on between-study comparisons are 
based on comparisons between non-compara-
ble groups as even when all the individual stud-
ies are RCTs, patients were not randomised to 
one study or another (Muirow & Oxman, 1994). 
The various statistical techniques that can be 
employed in subgroup analyses (Der Simoman 
& Laird, 1986) are again beyond the scope of 
this discussion. 
iv) Sensitivity analysis: This refers to evalua-
tions aimed at assessing how sensitive the re-
sults of the analysis are to the way the review 
was conducted. Changing inclusion criteria (ex-
cluding studies without operationally defined 
diagnostic criteria, or excluding very old trials), 
including or excluding studies of lower quality 
or with ambiguous inclusion criteria, excluding 
unpublished studies, reanalysing the data us-
ing different approaches to handling data (e.g.: 
intention to treat analysis versus analysis of 
completers) or different statistical techniques 
(random effects versus fixed effects), are com-
monly used decisions in sensitivity analyses. 
If the sensitivity analyses that are done 
do not materially change the results, it 
strengthens the confidence that can be placed 
in them. If the results change in a way that 
might lead to different conclusions this indicates 
a need for greater caution in interpreting the 
results and drawing conclusions, or it may 
generate hypotheses for further investigations 
(Muirow & Oxman, 1994). 
E. Interpreting results 
A common mistake that occurs in 
interpreting results when there is inconclusive 
evidence is to confuse 'no evidence of effect' 
with 'evidence of no effect'. The former reflects 
uncertainty while the latter indicates clear 
evidence exists to discredit a particular 
intervention. A second mistake sometimes 
committed is to arrive at conclusions not 
supported by the evidence in the review, or to 
make conclusions based on personal 
convictions inspite of evidence to the contrary 
presented in the review. 
Table 2 provides a summary checklist to 
aid readers to evaluate systematic reviews for 
possible biases. 
The science of meta-analysis is growing 
and attempts are constantly being made to im-
prove scientific quality. One such endeavour is 
the efforts of the Cochrane Collaboration. 
WHAT IS THE COCHRANE COLLABORA-
TION? 
The Cochrane Collaboration is an inter-
national network of individuals and institutions 
formed in 1993, and committed to preparing, 
maintaining and disseminating systematic re-
views of the effects of health care. Cochrane 
reviews are highly structured systematic reviews 
prepared by a group of collaborating authors, 
called a Cochrane review group, using explic-
itly refined methods to reduce bias. These re-
views are published in the Cochrane Library, 
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TABLE 2 
HOW TO EVALUATE A SYSTEMATIC REVIEW 
1. Are the results of the review valid ? 
• Does the review address a focused clinical question ? 
• Were inclusion criteria used to select articles 
appropriate ? 
• Was the search for. relevant studies through ? Is 
there a likelihood of publication bias? 
• Was the validity of included studies adequately 
assessed ? 
• Were benefits of the intervention as well as harmful 
effects assessed ? 
• Was the review based entirely on the results of small 
sample RCTs ? 
2. Was the data handled appropriately ? 
• Was data extraction from trials free from bias ? 
• Was there an attempt to obtain missing information 
from authors ? 
• Was an intention to treat analysis used ? 
• What is the magnitude of the effect ? How precise 
are the overall results of the review ? 
• Is it logical to combine results to produce a summary 
statistic ? Is there an absolute measure ? 
• Is there significant heterogeneity ? If so, can it be 
explained on methodological or clinical grounds ? 
• How sensitive are the results to changes in the way the 
analysis was done ? 
3. Are the conclusions generalisable ? 
• Are participants & Interventions of included studies 
relevant to your practice ? 
• Are the conclusions Justified by the evidence ? 
• Is 'no evidence of effect' interpreted as 'evidence of 
no effect' ? 
• Are subgroup analysis interpreted cautiously ? 
• Is the clinical significance of the results sufficient 
to warrant a change in our practice ? 
an electronic journal on CD and computer discs 
(and now showing on the Internet) released quar-
terly, which contains the Cochrane Database of 
Systematic Reviews (CDSR). These are up-to-
date reviews that are periodically updated in re-
sponse to comments and criticisms and when 
new data becomes available. The January 1998 
release contains 326 completed reviews and 
342 protocols of reviews underway covering a 
wide range of health problems. The eventual 
aims are to provide a database for clinicians, , 
policy makers and consumers on the effects of 
all treatments in all aspects of health care. 
The Cochrane Library also contains the 
Data Base of Abstracts of Reviews of 
Effectiveness (DARE) which has at present 
1554 abstracts of reviews published elsewhere 
but adjudged to fulfil criteria for systematic 
reviews. Perhaps the most innovative 
component of the Library is the largest register 
of controlled trials available anywhere, the 
Cochrane Controlled Trials Register (CCTR & 
CENTRAL)., This contains, in the January 1998 
release, abstracts of 1,58,065 randomised or 
controlled clinical trials, obtained from 
MEDLINE as well as from hand-searching 
scores of general and specialist health care 
journals. The Library also contains 646 
references in its Review Methodology Database 
pertaining to the science of systematic reviews 
and evidence based medicine. The Collabora-
tion is an enterprise that has been liked to the 
Human Genome Project in its scope and its 
potential implications for modern medicine 
(Naylor, 1997). 
The Collaboration has 15 centres world 
wide currently, with 47 active or proposed 
collaborative review groups of which 8 currently 
prepare reviews of interest to mental health 
professionals. The scope and relevance of the 
Collaboration's activities to mental health care 
is steadily increasing as new groups are formed 
and more people volunteer their services to the 
Collaboration. 
WHAT IS THE GOLD STANDARD - META-
ANALYSIS OR RANDOMISED CONTROLLED 
TRIALS? 
This is an area of current controversy with ! 
RCTs being considered as the gold standard of; 
efficacy in some quarters (Bailar, 1997) and 
meta-analysis considered the method provid-
ing the strongest evidence in others (Geddes & PSYCHIATRY AND THE COCHRANE COLLABORATION 
Harrison, 1997). Randomised controlled trials 
(provided randomisation is proper) guarantee 
avoidance of moderate biases that non-
randomised studies cannot avoid. Meta-analy-
sis based on non-randomised evidence are cer-
tainly open to bias. Similarly, though meta-analy-
sis are conducted on non-experimental studies 
(Brown, 1997; Harris & Barraclough, 1997), the 
science of meta-analysis of observational stud-
ies is in it's infancy and doubts have been raised 
on the validity of this approach due to the diffi-
culty in controlling biases and confounders 
(Feinstein, 1995; Shapiro, 1997). 
There is incontrovertible evidence, how-
ever, that large scale randomised trials - multi-
centered mega-trials involving tens of thousands 
of subjects such as the ISIS-4 (1995) - avoid 
random errors and yield definitive findings that 
improve the treatments of millions of patients. 
Alternatively, systematic reviews of large RCTs 
(> 1000 patients each) are a complementary 
strategy to mega-trials (e.g. : Fibrinolytic 
Therapy Trialists' Collaborative Group, 1994) 
and are to be relied on as the best available 
evidence in the absence of a mega-trial. On the 
other hand, meta-analysis based entirely on 
small randomised controlled trials are likely to 
give erroneous results, even if the magnitude 
of effect of the pooled results is large and sta-
tistically significant, and should be treated with 
caution (Egger & Smith, 1995). Thus numbers 
as well as quality seem to determine the gold 
standard (Table 3). 
TABLE 3 
HIERARCY OF THE STRENGTH OF THE EVIDENCE 











Large scale ("mega-trial) multicentred RCT 
Systematic review of large RCTs 
Systematic review of moderately large RCTs 
One moderately large RCT 
Systematic review of small RCTs 
One small RCT 
Non-Randomized controlled trial 
Cohort study 
Case-control or correlational study 
Case series 
EVIDENCE BASED PSYCHIATRY 
We would all like to believe that our 
practice of psychiatry is based on sound 
scientific evidence. In some centres psychiat-
ric practice is based on evidence to the same 
extent as in other medical disciplines (Geddes 
& Harrison, 1997). To find the best available 
evidence in order to answer clinical questions, 
easily accessible syntheses of updated 
information is a requisite and the Cochrane Li-
brary is a potential source of this information 
with much to offer mental health professionals. 
However, many completed reviews on mental 
health interventions in the Library, and 
elsewhere in the published literature, are based 
on small sample RCTs and should be interpreted 
with caution. For example, the review of ECT 
in schizophrenia (Tharyan, 1998) is based on 
only 11 trials that fulfilled selection criteria, and 
the largest comparison includes only 6 trials with 
153 ECT treated patients and 141 controls. It 
appears that large multi-centered randomised 
trials are required in some areas of mental 
health care, pending which the results of 
systematic reviews, however suspect, are our 
'best available evidence'. 
Caution is urged in generalising the 
results of randomised controlled trials to 
clinical practice. 
There often are significant differences 
between characterestics of included and 
excluded patients in RCTs (Licht et al., 1997). 
Whether this differentially affects outcome 
needs further enquiry. 
In the final analysis, good clinical 
medicine (and psychiatry) will always be both 
an art as well as a science; obtaining the best 
available evidence' could increase the amount 
of science in the blend. 
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